These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34585443)

  • 21. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
    Popp AW; Buffat H; Cavelti A; Windolf M; Perrelet R; Senn C; Lippuner K
    Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
    Cosman F; Cauley JA; Eastell R; Boonen S; Palermo L; Reid IR; Cummings SR; Black DM
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4546-54. PubMed ID: 25215556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
    Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC
    J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study.
    Eastell R; Boonen S; Cosman F; Reid IR; Palermo L; Cummings SR; Black DM
    J Bone Miner Res; 2015 Mar; 30(3):570-4. PubMed ID: 25214069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
    Watanabe D; Kimura T; Watanabe K; Takano H; Uehara Y; Minowa T; Yamashita A; Yoshikawa S; Mizushima A
    BMC Cancer; 2021 Apr; 21(1):422. PubMed ID: 33863312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study.
    Okimoto N; Sakai A; Yoshioka T; Kobayashi T; Asano K; Akahoshi S; Ishikura T; Fukuhara S; Fuse Y; Mizuno T; Katae Y; Matsumoto H; Ogawa T; Nishida S; Ikeda S; Menuki K; Saito J; Okazaki Y; Mizuno N; Fujiwara S
    J Bone Miner Metab; 2020 Mar; 38(2):230-239. PubMed ID: 31586241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.
    Bai H; Jing D; Guo A; Yin S
    J Int Med Res; 2013 Jun; 41(3):697-704. PubMed ID: 23669294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
    N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid and clinical fractures and mortality after hip fracture.
    Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
    N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
    Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
    Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.
    Bell KJ; Hayen A; Glasziou P; Irwig L; Eastell R; Harrison SL; Black DM; Bauer DC
    J Bone Miner Res; 2016 Sep; 31(9):1767-73. PubMed ID: 27027655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance.
    Takada J; Sato S; Arai K; Kito Y; Oshita Y; Saito K
    J Bone Miner Metab; 2023 Mar; 41(2):268-277. PubMed ID: 36862212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.